Vedolizumab and Ustekinumab Levels in Pregnant Women With Inflammatory Bowel Disease and Infants Exposed In Utero.

MLA

Prentice, Ralley, et al. “Vedolizumab and Ustekinumab Levels in Pregnant Women With Inflammatory Bowel Disease and Infants Exposed In Utero.” Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association, Mar. 2024. EBSCOhost, https://doi.org/10.1016/j.cgh.2024.02.025.

APA

Prentice, R., Flanagan, E., Wright, E. K., Gibson, P. R., Rosella, S., Rosella, O., Begun, J., An, Y.-K., Lawrance, I. C., Kamm, M. A., Sparrow, M., Goldberg, R., Prideaux, L., Vogrin, S., Kiburg, K. V., Ross, A. L., Burns, M., & Bell, S. J. (2024). Vedolizumab and Ustekinumab Levels in Pregnant Women With Inflammatory Bowel Disease and Infants Exposed In Utero. Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association. https://doi.org/10.1016/j.cgh.2024.02.025

Chicago

Prentice, Ralley, Emma Flanagan, Emily K Wright, Peter R Gibson, Sam Rosella, Ourania Rosella, Jakob Begun, et al. 2024. “Vedolizumab and Ustekinumab Levels in Pregnant Women With Inflammatory Bowel Disease and Infants Exposed In Utero.” Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association, March. doi:10.1016/j.cgh.2024.02.025.